ACT Genomics is a world-leading genomic test solution provider. Our mission is to make personalized medicine accessible to all.
We offer precision medicine services globally. Combining tumor biology, cancer genomics, and bioinformatics experts to provide treatment guidelines for solid tumors, relapse, and drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. We are dedicated to turning every cancer patients genetic information into actionable resolutions through cutting-edge next-generation sequencing (NGS) platforms, bioinformatics analysis, and comprehensive service offerings.
Our NGS platform, coupled with sophisticated bioinformatics tools and curated proprietary databases, enables us to deliver reliable results for clinical and research purposes, and our data visualization technologies make the scientific results easily understandable for everyone.
Our clinical services include cancer prevention, early detection, treatment selection, and disease monitoring. Our genomic assays offer comprehensive cancer genomic profiling and treatment options for patients with cancer and provide insights into biomarker discovery and patient stratification for clinical trials.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2014
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was ACT Genomics founded?
ACT Genomics was founded in 2014.
What industry is ACT Genomics in?
ACT Genomics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ACT Genomics based?
ACT Genomics is headquartered in Taipei, Taiwan.
Find investors for your startup like ACT Genomics
Gritt sends AI-personalised outreach to each investor — from your Gmail
